Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
Authors:
- 21 June 2018
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 171 (3) , 737-745
Abstract
The new eighth edition TNM classification by the AJCC for breast cancer (BC) incorporates biologic factors and gene expression prognostic panels, in addition to traditional anatomic factors. In this study, we evaluated the prognostic value of this new staging system compared to the previous AJCC 7th edition staging system.Keywords
This publication has 18 references indexed in Scilit:
- Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast CancerJAMA Oncology, 2018
- Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based settingBreast Cancer Research and Treatment, 2017
- Prospective Validation of a 21-Gene Expression Assay in Breast CancerNew England Journal of Medicine, 2015
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study populationThe Lancet Oncology, 2013
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsThe Lancet, 2011
- Ki67 in breast cancer: prognostic and predictive potentialThe Lancet Oncology, 2010
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403–410Histopathology, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002